Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD2811 |
Synonyms | |
Therapy Description |
AZD2811 is nanoparticle formulation of Barasertib (AZD1152), which inhibits Aurora kinase B to induce cell cycle arrest and results in tumor regression (PMID: 26865565, PMID: 28292940). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD2811 | AZD-2811|Barasertib-HQPA|Defosbarasertib | Aurkb Inhibitors 21 | AZD2811 is nanoparticle formulation of Barasertib (AZD1152), which inhibits Aurora kinase B to induce cell cycle arrest and results in tumor regression (PMID: 26865565, PMID: 28292940). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02579226 | Phase I | Irinotecan AZD2811 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03217838 | Phase Ib/II | AZD2811 | Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients. | Terminated | USA | AUS | 0 |